RESUMO
We investigated the impact of PGP on ethanol-induced mucosal damages and on the development of acetate gastric ulcers in rats for two ways of introduction--intraperitoneal and intragastric. PGP in the dozes of 0.1, 1 and 10 mg/kg authentically reduced the area of ethanol-induced mucosal damages at intraperitoneal introduction by 43, 70 and 65%, respectively; at intragastric introduction--by 64, 66 and 83%, respectively. Intraperitoneal introduction of PGP in the doze of 1 mg/kg and its intragastric introduction in the doze of 0.1 mg/kg equally reduced the development of acetate gastric ulcers by 73%. Thus, irrespective of the way of its introduction (intraperitoneal or intragastric) and its doze, PGP has a significant protective anti-ulcerous effect and reduces the development of acetate gastric ulcers in rats.
Assuntos
Ácido Acético/toxicidade , Etanol/toxicidade , Mucosa Gástrica/efeitos dos fármacos , Oligopeptídeos/uso terapêutico , Prolina/análogos & derivados , Prolina/uso terapêutico , Substâncias Protetoras/uso terapêutico , Úlcera Gástrica/prevenção & controle , Administração Oral , Animais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Injeções Intraperitoneais , Masculino , Oligopeptídeos/administração & dosagem , Prolina/administração & dosagem , Substâncias Protetoras/administração & dosagem , Ratos , Úlcera Gástrica/induzido quimicamenteRESUMO
The most stable regulatory peptides (RP) including the new family of RP (glyprolines) and derivatives of hybrid peptide MEHFPGP are characterized. High ability of glyprolines to penetrate into the blood-stream through the gastrointestinal tract is demonstrated. Antiulcer, antithrombotic and antidiabetic activities of glyprolines were discovered in experiments on white rats. The activity of oligopeptides PGP, PG and GP is compared. Mechanisms of glycoprolines activities and feasibility of their administration with connective tissue food proteins are discussed. Thus, glyprolines are perspective drugs for treatment of gastric ulcer, correction of hemostasis and thrombosis suppression prepared for preclinical trial.